Molecular and Clinical Insights into <i>TP53</i>-Mutated MDS and AML.

Int J Mol Sci · 2025 · PMC12652684 · PMID 41303305

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Unfortunately, in the phase III trial, eprenetapopt plus azacitidine did not reach statistical significance in the primary endpoint (12-month CR rate 35 vs. 22% with azacitidine alone) [ 124 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Molecular and Clinical Insights into &lt;i&gt;TP53&lt;/i&gt;-Mutated MDS and AML.

The sentences

Molecular and Clinical Insights into <i>TP53</i>-Mutated MDS and AML.